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Abstract With wide implementation of screening tests for the Human Papilloma Virus, the 
number of diagnosed cases of premalignant or early stages of cervical cancer has increased 
considerably. As a consequence, surgeons’ attention has focused on determining how best 
to limit the surgical procedure so the benefits of the procedure will not be surpassed by 
postoperative morbidity. In this respect, extended lymph node dissection, routinely 
associated so far with cervical cancer patients, has in the last decades been replaced with 
sentinel node detection and biopsy. Initially performed through radiocolloid injection, this 
method has undergone permanent changes in order to maximize its efficacy and safety. 
Although the laparoscopic approach had been widely used in the past, a new method has 
been proposed, i.e., the use of indocyanine green injection, which has yielded promising 
results for sentinel node detection in the early stages of cervical carcinoma. This paper 
reviews the literature of the most relevant studies conducted on this topic. 
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Highlights ✓ Sentinel lymph node detection by using indocyanine green injection seems to be a safe 
and effective method in cervical cancer patients. 
✓ Attention should be paid to the method of dilution and injection of this product, in order 
to avoid the association of false positive results. 
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Introduction 
The benefits of detecting the sentinel node were 
demonstrated in cases of solid tumors almost a century ago. 
More recently, the method again proved safe and effective 
in treating other gynecologic malignancies such as breast 
cancer and vulvar cancer (1-4). 
Regarding cervical cancer, the technique of sentinel 
node biopsy has been implemented since 1996 and 
consisted of blue dye and/or radiocolloid injection. 
Although the method had encouraging results, it 
nevertheless failed in detecting bilateral sentinel lymph 
nodes in almost half the patients. As a consequence, a 
significant number of patients were further subjected to 
extended lymph node dissection even though the malignant 
process had been diagnosed in an early stage of the disease 
(5, 6).  However, the failure to detect the sentinel nodes 
argued in favor of searching for a more specific tracer. 
Specifically, the administration of radioisotopes such as 
Technetium proved to be painful to the patient, expensive, 
challenging for the team, and even dangerous due to 
possible radioactive contamination after the injection (7, 
8). Other tracers such as blue dye, although less costly, 
were associated with rapid clearance from the sentinel 
nodes, meaning they could no longer be detected after a 
period of time. Specifically, due to the reduced dimensions 
of the molecules, these dyes seemed to be associated with 
a rapid migration from the level of the sentinel nodes. 
Therefore, by the time of surgery, the true sentinel nodes 
might be missed, while the blue dye accumulates at the 
level of the next lymph node stations. As a result, the rates 
of false positives increase and the effectiveness of the 
method decreases (9, 10). Moreover, the injection of such 
dyes is sometimes associated with allergic reactions, 
including anaphylactic shock (9-11). For these reasons, 
there was need to identify other types of tracers that could 
provide a higher rate of detection, with lower rates of 
adverse reactions and better identification of the sentinel 
nodes bilaterally (12).   
Discussions 
The utility of indocyanine green for sentinel lymph node 
detection in gynecologic malignancies. 
This method uses an indocyanine green injection 
(approved by the FDA for many years) and the near 
infrared fluorescence imaging, due to the fluorescent 
properties of this substance in the 700-900 nm light 
spectrum (13). According to a study by Jewell and 
colleagues, the method consists in diluting a 25 mg vial in 
20 cc of sterile water, thus obtaining a concentration of 
1.25 mg/ml, and injecting one cc at 3 pm and 9 pm in the 
superficial and deep layer respectively at the level of the 
uterine cervix. The injection was done just after draping the 
patient, but before the insertion of the uterine manipulator 
and prior to laparoscopic surgery (12). Another site of 
injection is the endocervical or intrauterine cavity during 
hysteroscopy. The intracervical injection has been 
associated with the best results due to the presence of rich 
parametrial lymphatic drainage. 
However, when the surgeon decides to inject the 
indocyanine green, several points should be considered: the 
product contains up to 5% iodine-based excipients, so it 
cannot be used in patients with known allergies to iodine; 
the substance should be diluted in sterile water and not in 
other substances such as sodium chloride (due to the fact 
that it is not readily soluble in saline solution), and the fact 
that the product is a negatively charged ion should be 
noted. Moreover, if the product is dissolved in saline 
solutions, the molecules trend to aggregate, influencing the 
optical properties (14, 15). In addition, once the product is 
dissolved, it should be kept in a dark room in order to 
preserve its fluorescent properties (16). 
An interesting study on the topic of the influence of the 
concentration and volume of the injected indocyanine 
green was conducted by Xiong et al. (2014). In this study, 
cases in which the concentration was lower than 5 mg/ml 
and the volume was higher than 2 ml were associated with 
the best rates of detection of sentinel nodes in cervical 
cancer patients (17). Furthermore, according to the 
National Comprehensive Cancer Network (NCCN) 
Guidelines, Version 1.2018, the indocyanine green 
injection should be administered at the level of the uterine 
cervix, while the sentinel nodes are usually located medial 
to the external iliac vessels, ventral to the internal iliac 
vessels or at the level of the superior area of the obturator 
fossa (18).  
However, debates regarding the protocol of 
indocyanine green injection in cervical cancer patients 
stem from the relatively low number of cases making use 
of this therapeutic protocol. Once the number of cases 
increases, a more standardized protocol can be expected. 
Moreover, similar to other malignancies, synchronous 
intracervical and intrauterine injection might also be 
considered. For colorectal cancer, some authors have 
proposed synchronous submucosal and subserosal 
injection with encouraging results (19). According to a 
meta-analysis by Emile, the submucosal and subserosal 
injection of indocyanine green in association with 
preoperative injection is correlated with a significantly 
higher rate of sentinel node detection (19).    
Sentinel node detection in cervical cancer 
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Indocyanine green sentinel node detection as part of a 
dual method 
To test the efficacy of the method, indocyanine green 
injection was initially used as part of a dual method of 
detection, in association with blue dye injection or with 
radiotracer administration. Jewel et al. (2014) analyzed the 
results of 227 patients with uterine malignancies submitted 
to surgery between 2011 and 2013 at the Memorial Sloan 
Kettering Cancer Center, in New York, the USA (12). 
Among these cases, the final histopathological studies 
confirmed the cervical origin of the malignancy in 18 
cases. Among the entire cohort, the median time for 
detecting the sentinel node following injection was 30 
minutes, while the median number of identified sentinel 
nodes was 3. Indocyanine green was used as a single 
method to detect the sentinel node in 87% of cases, while 
the remaining 13% of cases benefited from the dual method 
consisting of combined indocyanine green and blue dye 
injection. The authors reported no significant difference in 
terms of sentinel node detection after the indocyanine 
green injection alone or in association with blue dye 
injection. However, the rates of bilateral lymph node 
detection were an improvement over other techniques, thus 
demonstrating the efficacy of the method. Therefore, the 
overall detection rate was 95%, while the rate of bilateral 
detection was 79%. However, the authors underscore the 
fact that even if indocyanine green injection is used, the 
rates of detection are still poor among patients with a 
higher body mass index. The authors further observed that 
no additional lymph nodes were eventually found after blue 
dye injection when compared to indocyanine green 
injection, so they excluded the use of blue dye and injected 
only indocyanine green. As for the use of technetium, the 
higher rates of bilateral lymph node detection reported after 
indocyanine green injection as well as the various 
limitations of technetium injection (higher costs, exposure 
to radioactivity) led the authors to support the superiority 
of the fluorescent method (12).  
One of the more relevant studies demonstrating the 
safety and efficacy of indocyanine green injection in 
uterine cancer malignancies was conducted by Anabela 
Rocha and colleagues, published in 2016 (16). The article 
reviewed papers published on this topic between January 
2010 and May 2015, reviewing data from 10 studies 
involving 422 patients: 368 cases submitted to robotic 
surgery, 15 cases to laparoscopic surgery, and 10 cases to 
open surgery. Of these reports, six studies focused on 
cervical cancer patients. The authors emphasized the fact 
that the indocyanine green injection occurred at the level 
of the uterine cervix or directly into the uterine cavity 
through hysteroscopy. However, the intracervical injection 
was associated with a significantly higher rate of sentinel 
node detection. Among the reviewed studies, the mean 
number of retrieved lymph nodes was 4.7, no complication 
being related to the indocyanine green administration. 
Similar to the previous study, this paper also highlighted 
the importance of the indocyanine green injection in 
providing bilateral sentinel lymph node detection, the 
detection rates for bilateral mapping being of 97% for 
indocyanine green injection and 77% for blue dye 
injection. Moreover, studies which used indocyanine green 
alone or in association with isosulfan blue injection 
demonstrated that the detection rate was even higher when 
indocyanine green was administered alone. As for the 
method of injection, multiple techniques have been 
proposed. While most studies involved injecting 
indocyanine green at the level of the uterine cervix just 
before inducing the pneumoeperitoneum (in minimally 
invasive surgery) or just before performing the incision (in 
open surgery), other studies injected the dye directly in the 
uterine wall by hysteroscopy before beginning the surgical 
procedure. Moreover, other authors have injected the dye 
into the uterine cervix immediately after exposing the 
pelvic lymph nodes. As for the period of time between the 
injection and the intra-abdominal detection of the 
indocyanine green, various intervals (between 29 and 69 
minutes) have been reported. However, 30 minutes might 
be considered an approximate time of migration (16).  
In order to increase the rates of sentinel node detection 
after indocyanine green injection, some authors have 
proposed the combination of indocyanine green and human 
serum albumin. Currently, however, this combination has 
not demonstrated superiority, similar rates of sentinel node 
detection being reported for both two methods (20). 
Conclusions 
Sentinel lymph node detection by using indocyanine 
green injection seems to be a safe and effective method in 
cervical cancer patients. The method has been associated 
with increased rates of sentinel node detection and bilateral 
mapping while the rates of adverse reaction are almost null. 
Moreover, the method appears to improve results when 
used as a single agent or as part of a dual method. However, 
attention should be paid to the method of dilution and 
injection of this product in order to avoid the association of 
false positive results. 
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